
Language
Search
News
- Bruker Introduces SampleXpress™, a New and Easy-to-Use Autosampler that Delivers Increased...
- Bruker Announces Order by Kennedy Krieger Institute for Ultra-High Field 11.7 Tesla Pre-Clinical...
- Bruker Announces Major Multi-Systems NMR Order from Vanderbilt University
- MRI Newsletter 05/2010
- Bruker Introduces New Ascend™ High Performance High-Field NMR Magnet Series
Upcoming Events
Stroke
Cerebroprotective Drug Trials
Courtesy of M. Eis, M. Neumaier, U. Pschorn
Boehringer Ingelheim Pharma KG, Dept CNS Research, Ingelheim, Germany

- These data were acquired using a BioSpec 47/40
Rat brains at three time-points after an MCAO* insult, with (bottom row) and without (top row) cerebroprotective drug treatment. The compound reduces the growth of both lesion volume and its severity (note the very different lesion size at the outset).
*MCAO: Middle Cerebral Artery Occlusion
